Lisata Buys Marea, Raises $225M, Leaves Holders 2.39%

Lisata Therapeutics closed its acquisition of Marea Therapeutics and signed a definitive agreement for a concurrent private placement expected to raise approximately $225 million gross, the company announced on September 17. Financing completion was expected on September 18, subject to customary closing conditions.

The price for legacy shareholders is steep. Following both transactions, legacy equity holders of Lisata Therapeutics (NASDAQ:LSTA) would retain approximately 2.39% ownership on the stated fully diluted, as-converted basis, according to the company's disclosure. That calculation uses the treasury stock method and excludes beneficial ownership limits.

The redistribution of ownership is dramatic. Former Marea equity holders would own approximately 59.54% of the combined company, while private-placement investors would take approximately 38.07%. Existing Lisata investors are receiving exposure to a substantially different pipeline through a much smaller proportional stake.

The bull case: cash through the data

Lisata projects that the financing will support operations into 2028. Management expects fourth-quarter 2027 data from two studies: the MAR001 Phase 2b trial in severe hypertriglyceridemia, or very high triglyceride levels, and the MAR002 Phase 2 program in acromegaly, a disorder involving excess growth hormone. The projected funding period extends beyond those planned results.

For Lisata, that alignment between funding and clinical milestones is the strongest argument for the transaction. Completing patient studies could provide evidence to assess whether the acquired medicines warrant larger trials and further investment. Having resources available through expected results could also reduce pressure to seek capital before the programs produce meaningful data.

The two programs offer separate opportunities to establish clinical value. Successful results could support development partnerships or improve the terms of future financing. Those possibilities make the acquired assets and available capital central to assessing what the retained ownership might ultimately be worth.

The bear case: dilution and dependency

The dilution is substantial. On the disclosed basis, legacy investors now depend on the combined business becoming valuable enough to make their small remaining interest economically meaningful.

The ownership percentages alone cannot settle that valuation question. Investors need to weigh the acquired assets, financing proceeds and development obligations against the value of continuing with the previous business.

One procedural hurdle remains. Lisata needs shareholder approval to convert the Series C non-voting preferred stock into common shares. The acquisition and private placement themselves do not require that approval.

The deal now rests on execution: whether MAR001 and MAR002 deliver Phase 2 results in late 2027 that justify the stake legacy holders gave up to fund them.